SAN FRANCISCO, July 20, 2023 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that it will release financial results for the second quarter 2023 after the close of trading on Thursday, August 3, 2023. The company’s management team will host a corresponding conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET.
Investors interested in listening to the conference call may do so by accessing the live and archived webcast of the event available on the investors section of the Company’s website at investors.irhythmtech.com.
About iRhythm Technologies, Inc.
iRhythm is a leading digital health care company that creates trusted solutions that detect, predict, and prevent disease. Combining wearable biosensors and cloud-based data analytics with powerful proprietary algorithms, iRhythm distills data from millions of heartbeats into clinically actionable information. Through a relentless focus on patient care, iRhythm’s vision is to deliver better data, better insights, and better health for all.
Investor Relations Contact
Stephanie Zhadkevich
(919) 452-5430
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact
Saige Smith
(262) 289-7065
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$99.60 |
| Daily Change: | -0.35 -0.35 |
| Daily Volume: | 24,189 |
| Market Cap: | US$3.120B |
February 20, 2025 December 30, 2024 October 30, 2024 | |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
